Daniel W Bowles
Title | Associate Professor |
---|
Institution | University of Colorado Denver - Anschutz Medical Campus |
---|
Department | SOM-MED |
---|
|
|
|
Bibliographic
-
Ho AL, Foster NR, Zoroufy AJ, Campbell JD, Worden F, Price K, Adkins D, Bowles DW, Kang H, Burtness B, Sherman E, Morton R, Morris LGT, Nadeem Z, Katabi N, Munster P, Schwartz GK. Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404). J Clin Oncol. 2022 Jul 22; JCO2200229. PMID: 35867947.
-
Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, Hoff AO, Hitre E, Bowles DW, Hernando J, Faoro L, Banerjee K, Oliver JW, Keam B, Capdevila J. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021 08; 22(8):1126-1138. PMID: 34237250.
-
Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, Brose MS, Zhu VW, Leboulleux S, Bowles DW, Baik CS, Adkins D, Keam B, Matos I, Garralda E, Gainor JF, Lopes G, Lin CC, Godbert Y, Sarker D, Miller SG, Clifford C, Zhang H, Turner CD, Taylor MH. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021 08; 9(8):491-501. PMID: 34118198.
-
Grivas P, Khaki AR, Wise-Draper TM, French B, Hennessy C, Hsu CY, Shyr Y, Li X, Choueiri TK, Painter CA, Peters S, Rini BI, Thompson MA, Mishra S, Rivera DR, Acoba JD, Abidi MZ, Bakouny Z, Bashir B, Bekaii-Saab T, Berg S, Bernicker EH, Bilen MA, Bindal P, Bishnoi R, Bouganim N, Bowles DW, Cabal A, Caimi PF, Chism DD, Crowell J, Curran C, Desai A, Dixon B, Doroshow DB, Durbin EB, Elkrief A, Farmakiotis D, Fazio A, Fecher LA, Flora DB, Friese CR, Fu J, Gadgeel SM, Galsky MD, Gill DM, Glover MJ, Goyal S, Grover P, Gulati S, Gupta S, Halabi S, Halfdanarson TR, Halmos B, Hausrath DJ, Hawley JE, Hsu E, Huynh-Le M, Hwang C, Jani C, Jayaraj A, Johnson DB, Kasi A, Khan H, Koshkin VS, Kuderer NM, Kwon DH, Lammers PE, Li A, Loaiza-Bonilla A, Low CA, Lustberg MB, Lyman GH, McKay RR, McNair C, Menon H, Mesa RA, Mico V, Mundt D, Nagaraj G, Nakasone ES, Nakayama J, Nizam A, Nock NL, Park C, Patel JM, Patel KG, Peddi P, Pennell NA, Piper-Vallillo AJ, Puc M, Ravindranathan D, Reeves ME, Reuben DY, Rosenstein L, Rosovsky RP, Rubinstein SM, Salazar M, Schmidt AL, Schwartz GK, Shah MR, Shah SA, Shah C, Shaya JA, Singh SRK, Smits M, Stockerl-Goldstein KE, Stover DG, Streckfuss M, Subbiah S, Tachiki L, Tadesse E, Thakkar A, Tucker MD, Verma AK, Vinh DC, Weiss M, Wu JT, Wulff-Burchfield E, Xie Z, Yu PP, Zhang T, Zhou AY, Zhu H, Zubiri L, Shah DP, Warner JL, Lopes G. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium. Ann Oncol. 2021 06; 32(6):787-800. PMID: 33746047.
-
Weaver AN, Francisque F, Bowles DW. Tumor Regression After Treatment With Lenvatinib in FGFR2-Mutated Ameloblastoma. JCO Precis Oncol. 2020 Nov; 4:1403-1406. PMID: 35050789.
-
George B, Wen X, Mercke N, Gomez M, O'Bryant C, Bowles DW, Hu Y, Hogan SL, Joy MS, Aleksunes LM. Time-dependent changes in kidney injury biomarkers in patients receiving multiple cycles of cisplatin chemotherapy. Toxicol Rep. 2020; 7:571-576. PMID: 32382514.
-
Pozdeyev N, Rose MM, Bowles DW, Schweppe RE. Molecular therapeutics for anaplastic thyroid cancer. Semin Cancer Biol. 2020 04; 61:23-29. PMID: 31991166.
-
Vinogradskiy Y, Diot Q, Jones B, Castillo R, Castillo E, Kwak J, Bowles D, Grills I, Myziuk N, Guerrero T, Stevens C, Schefter T, Gaspar LE, Kavanagh B, Miften M, Rusthoven C. Evaluating Positron Emission Tomography-Based Functional Imaging Changes in the Heart After Chemo-Radiation for Patients With Lung Cancer. Int J Radiat Oncol Biol Phys. 2020 04 01; 106(5):1063-1070. PMID: 31983558.
-
Doebele RC, Drilon A, Paz-Ares L, Siena S, Shaw AT, Farago AF, Blakely CM, Seto T, Cho BC, Tosi D, Besse B, Chawla SP, Bazhenova L, Krauss JC, Chae YK, Barve M, Garrido-Laguna I, Liu SV, Conkling P, John T, Fakih M, Sigal D, Loong HH, Buchschacher GL, Garrido P, Nieva J, Steuer C, Overbeck TR, Bowles DW, Fox E, Riehl T, Chow-Maneval E, Simmons B, Cui N, Johnson A, Eng S, Wilson TR, Demetri GD. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020 02; 21(2):271-282. PMID: 31838007.
-
Kurzrock R, Bowles DW, Kang H, Meric-Bernstam F, Hainsworth J, Spigel DR, Bose R, Burris H, Sweeney CJ, Beattie MS, Blotner S, Schulze K, Cuchelkar V, Swanton C. Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. Ann Oncol. 2020 03; 31(3):412-421. PMID: 32067683.
-
Patil T, Simons E, Mushtaq R, Pacheco JM, Doebele RC, Bowles DW. Targeted therapies for ROS1-rearranged non-small cell lung cancer. Drugs Today (Barc). 2019 Oct; 55(10):641-652. PMID: 31720561.
-
McDermott JD, Bowles DW. Epidemiology of Head and Neck Squamous Cell Carcinomas: Impact on Staging and Prevention Strategies. Curr Treat Options Oncol. 2019 04 22; 20(5):43. PMID: 31011837.
-
Hernandez AL, Wang Y, Somerset HL, Keysar SB, Aisner DL, Marshall C, Bowles DW, Karam SD, Raben D, Jimeno A, Varella-Garcia M, Wang XJ. Inter- and intra-tumor heterogeneity of SMAD4 loss in head and neck squamous cell carcinomas. Mol Carcinog. 2019 05; 58(5):666-673. PMID: 30575147.
-
Kluger BM, Shattuck J, Berk J, Sebring K, Jones W, Brunetti F, Fairmont I, Bowles DW, Sillau S, Bekelman DB. Defining Palliative Care Needs in Parkinson's Disease. Mov Disord Clin Pract. 2019 Feb; 6(2):125-131. PMID: 30838311.
-
Ferris RL, Saba NF, Gitlitz BJ, Haddad R, Sukari A, Neupane P, Morris JC, Misiukiewicz K, Bauman JE, Fenton M, Jimeno A, Adkins DR, Schneider CJ, Sacco AG, Shirai K, Bowles DW, Gibson M, Nwizu T, Gottardo R, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Cohen EEW. Effect of Adding Motolimod to Standard Combination Chemotherapy and Cetuximab Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck: The Active8 Randomized Clinical Trial. JAMA Oncol. 2018 11 01; 4(11):1583-1588. PMID: 29931076.
-
Ibrahim ME, Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant CL, Bowles DW, George B, Wen X, Buckley B, Aleksunes L, Joy MS. Pharmacokinetic determinants of cisplatin-induced subclinical kidney injury in oncology patients. Eur J Clin Pharmacol. 2019 Jan; 75(1):51-57. PMID: 30220072.
-
Agrawal VR, Jodon G, Mushtaq R, Bowles DW. Update on multikinase inhibitor therapy for differentiated thyroid cancer. Drugs Today (Barc). 2018 Sep; 54(9):535-545. PMID: 30303494.
-
Karam SD, Reddy K, Blatchford PJ, Waxweiler T, DeLouize AM, Oweida A, Somerset H, Marshall C, Young C, Davies KD, Kane M, Tan AC, Wang XJ, Jimeno A, Aisner DL, Bowles DW, Raben D. Final Report of a Phase I Trial of Olaparib with Cetuximab and Radiation for Heavy Smoker Patients with Locally Advanced Head and Neck Cancer. Clin Cancer Res. 2018 10 15; 24(20):4949-4959. PMID: 30084837.
-
Pozdeyev N, Gay LM, Sokol ES, Hartmaier R, Deaver KE, Davis S, French JD, Borre PV, LaBarbera DV, Tan AC, Schweppe RE, Fishbein L, Ross JS, Haugen BR, Bowles DW. Genetic Analysis of 779 Advanced Differentiated and Anaplastic Thyroid Cancers. Clin Cancer Res. 2018 07 01; 24(13):3059-3068. PMID: 29615459.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29461908.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28753897.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28961851.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 27541166.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28002630.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28301079.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 28650002.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30977524.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 30539168.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 29981925.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 33773145.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 34125313.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 17926799.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22146228.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22268404.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 22106555.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 16939961.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 23942080.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24926548.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 24916771.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25593016.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 25893296.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 26936027.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 34410225.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 34767934.
-
Rulifson G, Bielefeldt AR. Evolution of Students' Varied Conceptualizations About Socially Responsible Engineering: A Four Year Longitudinal Study. Sci Eng Ethics. 2019 06; 25(3):939-974. PMID: 35018293.
-
Keysar SB, Eagles JR, Miller B, Jackson BC, Chowdhury FN, Reisinger J, Chimed TS, Le PN, Morton JJ, Somerset HL, Varella-Garcia M, Tan AC, Song JI, Bowles DW, Reyland ME, Jimeno A. Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res. 2018 06 15; 24(12):2935-2943. PMID: 29555661.
-
Necchi A, Pond GR, Pal SK, Agarwal N, Bowles DW, Plimack ER, Yu EY, Ladoire S, Baniel J, Crabb S, Niegisch G, Srinivas S, Berthold DR, Rosenberg JE, Powles T, Bamias A, Harshman LC, Bellmunt J, Galsky MD. Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. Clin Genitourin Cancer. 2018 04; 16(2):e483-e490. PMID: 29158079.
-
Leong S, Moss RA, Bowles DW, Ware JA, Zhou J, Spoerke JM, Lackner MR, Shankar G, Schutzman JL, van der Noll R, Voest EE, Schellens JHM. A Phase I Dose-Escalation Study of the Safety and Pharmacokinetics of Pictilisib in Combination with Erlotinib in Patients with Advanced Solid Tumors. Oncologist. 2017 12; 22(12):1491-1499. PMID: 28798270.
-
Chang C, Hu Y, Hogan SL, Mercke N, Gomez M, O'Bryant C, Bowles DW, George B, Wen X, Aleksunes LM, Joy MS. Pharmacogenomic Variants May Influence the Urinary Excretion of Novel Kidney Injury Biomarkers in Patients Receiving Cisplatin. Int J Mol Sci. 2017 Jun 22; 18(7). PMID: 28640195.
-
Rusthoven CG, Lanning RM, Jones BL, Amini A, Koshy M, Sher DJ, Bowles DW, McDermott JD, Jimeno A, Karam SD. Metastatic nasopharyngeal carcinoma: Patterns of care and survival for patients receiving chemotherapy with and without local radiotherapy. Radiother Oncol. 2017 07; 124(1):139-146. PMID: 28433411.
-
Wang K, McDermott JD, Schrock AB, Elvin JA, Gay L, Karam SD, Raben D, Somerset H, Ali SM, Ross JS, Bowles DW. Comprehensive genomic profiling of salivary mucoepidermoid carcinomas reveals frequent BAP1, PIK3CA, and other actionable genomic alterations. Ann Oncol. 2017 04 01; 28(4):748-753. PMID: 28327999.
-
Necchi A, Pond GR, Smaldone MC, Pal SK, Chan K, Wong YN, Viterbo R, Sonpavde G, Harshman LC, Crabb S, Alva A, Chowdhury S, De Giorgi U, Srinivas S, Agarwal N, Bamias A, Baniel J, Golshayan AR, Ladoire S, Sternberg CN, Cerbone L, Yu EY, Bellmunt J, Vaishampayan U, Niegisch G, Hussain S, Bowles DW, Morales-Barrera R, Milowsky MI, Theodore C, Berthold DR, Sridhar SS, Powles T, Rosenberg JE, Galsky MD. Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study. Eur Urol Focus. 2018 12; 4(6):937-945. PMID: 28753879.
-
Stokes WA, Jones BL, Bhatia S, Oweida AJ, Bowles DW, Raben D, Goddard JA, McDermott JD, Karam SD. A comparison of overall survival for patients with T4 larynx cancer treated with surgical versus organ-preservation approaches: A National Cancer Data Base analysis. Cancer. 2017 Feb 15; 123(4):600-608. PMID: 27727461.
-
Necchi A, Sonpavde G, Lo Vullo S, Giardiello D, Bamias A, Crabb SJ, Harshman LC, Bellmunt J, De Giorgi U, Sternberg CN, Cerbone L, Ladoire S, Wong YN, Yu EY, Chowdhury S, Niegisch G, Srinivas S, Vaishampayan UN, Pal SK, Agarwal N, Alva A, Baniel J, Golshayan AR, Morales-Barrera R, Bowles DW, Milowsky MI, Theodore C, Berthold DR, Daugaard G, Sridhar SS, Powles T, Rosenberg JE, Galsky MD, Mariani L. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Eur Urol. 2017 02; 71(2):281-289. PMID: 27726966.
-
Wang K, Russell JS, McDermott JD, Elvin JA, Khaira D, Johnson A, Jennings TA, Ali SM, Murray M, Marshall C, Oldham DS, Washburn D, Wong SJ, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Serracino HS, Ross JS, Bowles DW. Profiling of 149 Salivary Duct Carcinomas, Carcinoma Ex Pleomorphic Adenomas, and Adenocarcinomas, Not Otherwise Specified Reveals Actionable Genomic Alterations. Clin Cancer Res. 2016 Dec 15; 22(24):6061-6068. PMID: 27334835.
-
Bowles DW, Deutsch E, Raben D. Successes and Failures of Combined Modality Therapies in Head and Neck Cancer. Semin Radiat Oncol. 2016 10; 26(4):299-306. PMID: 27619251.
-
Bowles DW, Kochenderfer M, Cohn A, Sideris L, Nguyen N, Cline-Burkhardt V, Schnadig I, Choi M, Nabell L, Chaudhry A, Ruxer R, Ucar A, Hausman D, Walker L, Spira A, Jimeno A. A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clin Colorectal Cancer. 2016 12; 15(4):337-344.e2. PMID: 27118441.
-
Amini A, Jasem J, Jones BL, Robin TP, McDermott JD, Bhatia S, Raben D, Jimeno A, Bowles DW, Karam SD. Predictors of overall survival in human papillomavirus-associated oropharyngeal cancer using the National Cancer Data Base. Oral Oncol. 2016 May; 56:1-7. PMID: 27086480.
-
Amini A, Jones BL, McDermott JD, Serracino HS, Jimeno A, Raben D, Ghosh D, Bowles DW, Karam SD. Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base. Cancer. 2016 05 15; 122(10):1533-43. PMID: 26969811.
-
Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb; 53:74-9. PMID: 26705064.
-
Diamond JR, Wu B, Agarwal N, Bowles DW, Lam ET, Werner TL, Rasmussen E, Gamelin E, Soto F, Friberg G, Sun YN, Sharma S. Pharmacokinetic drug-drug interaction study of the angiopoietin-1/angiopoietin-2-inhibiting peptibody trebananib (AMG 386) and paclitaxel in patients with advanced solid tumors. Invest New Drugs. 2015 Jun; 33(3):691-9. PMID: 25895965.
-
Goldman J, Eckhardt SG, Borad MJ, Curtis KK, Hidalgo M, Calvo E, Ryan DP, Wirth LJ, Parikh A, Partyka J, Faessel H, Gangolli E, Stewart S, Rosen LS, Bowles DW. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res. 2015 Mar 01; 21(5):1002-9. PMID: 25501576.
-
Amini A, McDermott JD, Gan G, Bhatia S, Sumner W, Fisher CM, Jimeno A, Bowles DW, Raben D, Karam SD. Stereotactic body radiotherapy as primary therapy for head and neck cancer in the elderly or patients with poor performance. Front Oncol. 2014; 4:274. PMID: 25340041.
-
Kessler ER, Moss A, Eckhardt SG, Laudenslager ML, Kilbourn K, Mauss IB, Bowles DW, Hecker S, Fairclough DL, Kutner JS. Distress among caregivers of phase I trial participants: a cross-sectional study. Support Care Cancer. 2014 Dec; 22(12):3331-40. PMID: 25120010.
-
Ettinger DS, Handorf CR, Agulnik M, Bowles DW, Cates JM, Cristea M, Dotan E, Eaton KD, Fidias PM, Gierada D, Gilcrease GW, Godby K, Iyer R, Lenzi R, Phay J, Rashid A, Saltz L, Schwab RB, Shulman LN, Smerage JB, Stevenson MM, Varadhachary GR, Zager JS, Zhen WK, Bergman MA, Freedman-Cass DA. Occult primary, version 3.2014. J Natl Compr Canc Netw. 2014 Jul; 12(7):969-74. PMID: 24994917.
-
Bowles DW, McDermott JD, Jimeno A. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation. Future Oncol. 2014 May; 10(6):1065-80. PMID: 24941990.
-
Bowles DW, Diamond JR, Lam ET, Weekes CD, Astling DP, Anderson RT, Leong S, Gore L, Varella-Garcia M, Vogler BW, Keysar SB, Freas E, Aisner DL, Ren C, Tan AC, Wilhelm F, Maniar M, Eckhardt SG, Messersmith WA, Jimeno A. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1656-65. PMID: 24493827.
-
Bowles DW, Weickhardt A, Jimeno A. Afatinib for the treatment of patients with EGFR-positive non-small cell lung cancer. Drugs Today (Barc). 2013 Sep; 49(9):523-35. PMID: 24086949.
-
Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, Frederick BA, Varella-Garcia M, Tan AC, Jimeno A. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther. 2013 Oct; 12(10):1994-2005. PMID: 23873848.
-
Berge EM, Bowles DW, Flaig TW, Lam ET, Jimeno A. Tivozanib: practical implications for renal cell carcinoma and other solid tumors. Drugs Today (Barc). 2013 May; 49(5):303-15. PMID: 23724410.
-
Keysar SB, Le PN, Anderson RT, Morton JJ, Bowles DW, Paylor JJ, Vogler BW, Thorburn J, Fernandez P, Glogowska MJ, Takimoto SM, Sehrt DB, Gan GN, Eagles-Soukup JR, Serracino H, Hirsch FR, Lucia MS, Thorburn A, Song JI, Wang XJ, Jimeno A. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. Cancer Res. 2013 Jun 01; 73(11):3381-92. PMID: 23576557.
-
Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, Macfadden SM, Helber RM, Peterson S, Hausman DF, Said S, Leem TH, Goddard JA, Arcaroli JJ, Messersmith WA, Robinson WA, Hirsch FR, Varella-Garcia M, Raben D, Wang XJ, Song JI, Tan AC, Jimeno A. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Mol Oncol. 2013 Aug; 7(4):776-90. PMID: 23607916.
-
Kessler ER, Bowles DW, Flaig TW, Lam ET, Jimeno A. Axitinib, a new therapeutic option in renal cell carcinoma. Drugs Today (Barc). 2012 Oct; 48(10):633-44. PMID: 23110259.
-
Thienelt CD, Green K, Bowles DW. New and established tyrosine kinase inhibitors for chronic myeloid leukemia. Drugs Today (Barc). 2012 Sep; 48(9):601-13. PMID: 23032801.
-
Amaria RN, Bowles DW, Lewis KD, Jimeno A. Vismodegib in basal cell carcinoma. Drugs Today (Barc). 2012 Jul; 48(7):459-67. PMID: 22844657.
-
Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82. PMID: 22693357.
-
Bowles DW, Weickhardt AJ, Doebele RC, Camidge DR, Jimeno A. Crizotinib for the treatment of patients with advanced non-small cell lung cancer. Drugs Today (Barc). 2012 Apr; 48(4):271-82. PMID: 22536569.
-
Bowles DW, O'Bryant CL, Camidge DR, Jimeno A. The intersection between cannabis and cancer in the United States. Crit Rev Oncol Hematol. 2012 Jul; 83(1):1-10. PMID: 22019199.
-
Bowles DW, Jimeno A. New phosphatidylinositol 3-kinase inhibitors for cancer. Expert Opin Investig Drugs. 2011 Apr; 20(4):507-18. PMID: 21395485.
-
Bowles DW, Truesdale AE, Levi M, Trotter JF. Enterobacter cancerogenus bacteremia in a patient with poor dentition, cirrhosis, and a variceal bleed. J Clin Gastroenterol. 2006 May-Jun; 40(5):456-7. PMID: 16721236.
This graph shows the total number of publications by year, by first, middle/unknown, or last author.
To see the data from this visualization as text, click here.
Year | Publications |
---|
2006 | 1 | 2011 | 2 | 2012 | 5 | 2013 | 5 | 2014 | 6 | 2015 | 2 | 2016 | 7 | 2017 | 6 | 2018 | 33 | 2019 | 5 | 2020 | 4 | 2021 | 3 | 2022 | 1 |
To return to the timeline, click here.
|
Bowles's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|